{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:38:56Z","timestamp":1779889136160,"version":"3.53.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"DOI":"10.1182\/bloodadvances.2024012737","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:55:46Z","timestamp":1714676146000},"page":"3464-3467","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-163X","authenticated-orcid":false,"given":"Ramya","family":"Ramachandran","sequence":"first","affiliation":[{"name":"1Medical City Healthcare, Hospital Corporation of America, Arlington, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6784-0058","authenticated-orcid":false,"given":"Darshi","family":"Shah","sequence":"additional","affiliation":[{"name":"2Renaissance School of Medicine at Stony Brook University, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-9566","authenticated-orcid":false,"given":"Catherine","family":"Luo","sequence":"additional","affiliation":[{"name":"2Renaissance School of Medicine at Stony Brook University, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-9455","authenticated-orcid":false,"given":"Veer","family":"Shah","sequence":"additional","affiliation":[{"name":"3Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"4Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Multiple Myeloma and Amyloidosis Program, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Multiple Myeloma and Amyloidosis Program, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"1","key":"2024070913003101200_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"19","key":"2024070913003101200_bib2","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024070913003101200_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024070913003101200_bib4","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"2024070913003101200_bib5","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2024070913003101200_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"4","key":"2024070913003101200_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2017.1370421","article-title":"Attitudes about when and how to treat patients with AL amyloidosis: an international survey","volume":"24","author":"Milani","year":"2017","journal-title":"Amyloid"},{"issue":"20","key":"2024070913003101200_bib8","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1182\/bloodadvances.2023010324","article-title":"Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis","volume":"7","author":"Gustine","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2024070913003101200_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.18733","article-title":"First report of outcomes in patients with stage IIIb AL amyloidosis treated with dara-VCD front-line therapy","volume":"201","author":"Chakraborty","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2024070913003101200_bib10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.27179","article-title":"Reduced early mortality with daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study","volume":"99","author":"Chakraborty","year":"2024","journal-title":"Am J Hematol"},{"key":"2024070913003101200_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/PROM.S146849","article-title":"Psychometric validation of the SF-36 health survey in light chain amyloidosis: results from community-based and clinic-based samples","volume":"8","author":"White","year":"2017","journal-title":"Patient Relat Outcome Meas"},{"issue":"2","key":"2024070913003101200_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13506129.2020.1713743","article-title":"The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis","volume":"27","author":"D'Souza","year":"2020","journal-title":"Amyloid"},{"issue":"2","key":"2024070913003101200_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-021-00412-8","article-title":"Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change","volume":"11","author":"D'Souza","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"2024070913003101200_bib14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.26536","article-title":"Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u00a0\u00b1 daratumumab: results from the ANDROMEDA study","volume":"97","author":"Sanchorawala","year":"2022","journal-title":"Am J Hematol"},{"key":"2024070913003101200_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","article-title":"Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the Amyloidosis Forum HRQOL Working Group","volume":"14","author":"Rizio","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"issue":"36","key":"2024070913003101200_bib16","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024070913003101200_bib17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2024070913003101200_bib18","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2024070913003101200_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-020-00354-7","article-title":"Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"10","author":"Sarosiek","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"2024070913003101200_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024070913003101200_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/leu.2017.286","article-title":"Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains","volume":"32","author":"Sidana","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2024070913003101200_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024070913003101200_bib23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2024070913003101200_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal - the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3464\/2233820\/blooda_adv-2024-012737-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3464\/2233820\/blooda_adv-2024-012737-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:01:23Z","timestamp":1720530083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3464\/515997\/The-clinical-trials-landscape-in-immunoglobulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012737","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}